Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Trigemil Neuralgia (Tic Douloureux) - Overview
Trigemil Neuralgia (Tic Douloureux) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Trigemil Neuralgia (Tic Douloureux) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Trigemil Neuralgia (Tic Douloureux) - Companies Involved in Therapeutics Development
Amgen Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Coda Biotherapeutics Inc
Grace Therapeutics LLC
InMed Pharmaceuticals Inc
Noema Pharma AG
Noveome Biotherapeutics Inc
OliPass Corporation
Praxis Precision Medicines Inc
USA Elixiria Biotech Inc
Trigemil Neuralgia (Tic Douloureux) - Drug Profiles
DKI-561 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-00824 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Trigemil Neuralgia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INM-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOE-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLP-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRAX-562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rimegepant sulfate ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigemil Neuralgia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vixotrigine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Trigemil Neuralgia (Tic Douloureux) - Dormant Projects
Trigemil Neuralgia (Tic Douloureux) - Product Development Milestones
Featured News & Press Releases
Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigemil neuralgia trial
Sep 23, 2014: Convergence Pharmaceuticals’ Novel v1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy
Jun 16, 2014: Convergence Pharmaceuticals’ Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigemil Neuralgia Study
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Desigtion for v1.7 Blocking Pain Drug CNV1014802
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigemil Neuralgia Study
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigemil Neuralgia Study Of CNV-1014802
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigemil Neuralgia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Amgen Inc, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biogen Inc, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Coda Biotherapeutics Inc, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Grace Therapeutics LLC, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by InMed Pharmaceuticals Inc, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Noema Pharma AG, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Noveome Biotherapeutics Inc, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by OliPass Corporation, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Praxis Precision Medicines Inc, 2021
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by USA Elixiria Biotech Inc, 2021
Trigeminal Neuralgia (Tic Douloureux) - Dormant Projects, 2021